PDCD1 and neoplasm: To understand the kinetics of pembrolizumab binding its target in vivo, PD-1, in the peripheral blood and the tumor, PD-1 expression was detected by flow cytometry at discrete time points after treatment with pembrolizumab using clone EH12.2H7, which is blocked by pembrolizumab.